Press Room

In a statement released on February 15, 2024, by Charcot-Marie-Tooth Association (CMTA) Alliance Partner, Applied Therapeutics, the company said that its INSPIRE Phase III trial for a certain type of Charcot-Marie-Tooth disease (CMT), called SORD-deficiency, ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research that’s aimed at bringing treatments and a cure to patients of this rare disease, is pleased to announce the appointment of Dr. ...

GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced Nov. 6 that Suzanne (Sue) Bruhn, PhD, an accomplished biotech executive with extensive experience in the development and commercialization of treatments for rare diseases, will ...

The Charcot-Marie-Tooth (CMT) Association announced a $33,000 grant on April 25 that will enable Maurizio D’Antonio, PhD, to establish if molecules that selectively activate the ATF6 pathway of the Unfolded Protein Response (UPR) can engage ...

In a suite of exciting appointments, the Charcot-Marie-Tooth Association (CMTA) Strategy to Accelerate Research (STAR) Advisory Board is delighted to announce the appointment of Dr. Vera Fridman to their Clinical Expert Board (CEB). The CEB ...